VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model
Successful embryo implantation occurs followed by a local pro-inflammatory response subsequently shifted toward a tolerogenic one. VIP (vasoactive intestinal peptide) has embryotrofic, anti-inflammatory and tolerogenic effects. In this sense, we investigated whether the in vivo treatment with VIP co...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | JOUR |
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/20.500.12110/paper_20452322_v6_n_p_Gallino |
| Aporte de: |
| id |
todo:paper_20452322_v6_n_p_Gallino |
|---|---|
| record_format |
dspace |
| spelling |
todo:paper_20452322_v6_n_p_Gallino2023-10-03T16:38:14Z VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model Gallino, L. Calo, G. Hauk, V. Fraccaroli, L. Grasso, E. Vermeulen, M. Leirós, C.P. Ramhorst, R. cytokine retinoid related orphan receptor gamma vasoactive intestinal polypeptide vasoactive intestinal polypeptide receptor animal biosynthesis CBA mouse DBA mouse drug effects female genetics macrophage male metabolism mouse nidation phagocytosis physiology tumor microenvironment Animals Cellular Microenvironment Cytokines Embryo Implantation Female Macrophages Male Mice Mice, Inbred CBA Mice, Inbred DBA Nuclear Receptor Subfamily 1, Group F, Member 3 Phagocytosis Receptors, Vasoactive Intestinal Peptide Vasoactive Intestinal Peptide Successful embryo implantation occurs followed by a local pro-inflammatory response subsequently shifted toward a tolerogenic one. VIP (vasoactive intestinal peptide) has embryotrofic, anti-inflammatory and tolerogenic effects. In this sense, we investigated whether the in vivo treatment with VIP contributes to an immunosuppressant local microenvironment associated with an improved pregnancy outcome in the CBA/JxDBA/2 resorption prone model. Pregnancy induced the expression of VIP, VPAC1 and VPAC2 in the uterus from CBA/JxDBA/2 mating females on day 8.5 of gestation compared with non-pregnant mice. VIP treatment (2nmol/mouse i.p.) on day 6.5 significantly increased the number of viable implantation sites and improved the asymmetric distribution of implanted embryos. This effect was accompanied by a decrease in RORγt and an increase in TGF-β and PPARγ expression at the implantation sites. Moreover, VIP modulated the maternal peritoneal macrophages efferocytosis ability, tested using latex beads-FITC or apoptotic thymocytes, displaying an increased frequency of IL-10-producer F4/80 cells while did not modulate TNF-α and IL-12 secretion. The present data suggest that VIP treatment increases the number of viable embryos associated with an increase in the efferocytic ability of maternal macrophages which is related to an immunosuppressant microenvironment. © 2016, Nature Publishing Group. All rights reserved. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_20452322_v6_n_p_Gallino |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
cytokine retinoid related orphan receptor gamma vasoactive intestinal polypeptide vasoactive intestinal polypeptide receptor animal biosynthesis CBA mouse DBA mouse drug effects female genetics macrophage male metabolism mouse nidation phagocytosis physiology tumor microenvironment Animals Cellular Microenvironment Cytokines Embryo Implantation Female Macrophages Male Mice Mice, Inbred CBA Mice, Inbred DBA Nuclear Receptor Subfamily 1, Group F, Member 3 Phagocytosis Receptors, Vasoactive Intestinal Peptide Vasoactive Intestinal Peptide |
| spellingShingle |
cytokine retinoid related orphan receptor gamma vasoactive intestinal polypeptide vasoactive intestinal polypeptide receptor animal biosynthesis CBA mouse DBA mouse drug effects female genetics macrophage male metabolism mouse nidation phagocytosis physiology tumor microenvironment Animals Cellular Microenvironment Cytokines Embryo Implantation Female Macrophages Male Mice Mice, Inbred CBA Mice, Inbred DBA Nuclear Receptor Subfamily 1, Group F, Member 3 Phagocytosis Receptors, Vasoactive Intestinal Peptide Vasoactive Intestinal Peptide Gallino, L. Calo, G. Hauk, V. Fraccaroli, L. Grasso, E. Vermeulen, M. Leirós, C.P. Ramhorst, R. VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model |
| topic_facet |
cytokine retinoid related orphan receptor gamma vasoactive intestinal polypeptide vasoactive intestinal polypeptide receptor animal biosynthesis CBA mouse DBA mouse drug effects female genetics macrophage male metabolism mouse nidation phagocytosis physiology tumor microenvironment Animals Cellular Microenvironment Cytokines Embryo Implantation Female Macrophages Male Mice Mice, Inbred CBA Mice, Inbred DBA Nuclear Receptor Subfamily 1, Group F, Member 3 Phagocytosis Receptors, Vasoactive Intestinal Peptide Vasoactive Intestinal Peptide |
| description |
Successful embryo implantation occurs followed by a local pro-inflammatory response subsequently shifted toward a tolerogenic one. VIP (vasoactive intestinal peptide) has embryotrofic, anti-inflammatory and tolerogenic effects. In this sense, we investigated whether the in vivo treatment with VIP contributes to an immunosuppressant local microenvironment associated with an improved pregnancy outcome in the CBA/JxDBA/2 resorption prone model. Pregnancy induced the expression of VIP, VPAC1 and VPAC2 in the uterus from CBA/JxDBA/2 mating females on day 8.5 of gestation compared with non-pregnant mice. VIP treatment (2nmol/mouse i.p.) on day 6.5 significantly increased the number of viable implantation sites and improved the asymmetric distribution of implanted embryos. This effect was accompanied by a decrease in RORγt and an increase in TGF-β and PPARγ expression at the implantation sites. Moreover, VIP modulated the maternal peritoneal macrophages efferocytosis ability, tested using latex beads-FITC or apoptotic thymocytes, displaying an increased frequency of IL-10-producer F4/80 cells while did not modulate TNF-α and IL-12 secretion. The present data suggest that VIP treatment increases the number of viable embryos associated with an increase in the efferocytic ability of maternal macrophages which is related to an immunosuppressant microenvironment. © 2016, Nature Publishing Group. All rights reserved. |
| format |
JOUR |
| author |
Gallino, L. Calo, G. Hauk, V. Fraccaroli, L. Grasso, E. Vermeulen, M. Leirós, C.P. Ramhorst, R. |
| author_facet |
Gallino, L. Calo, G. Hauk, V. Fraccaroli, L. Grasso, E. Vermeulen, M. Leirós, C.P. Ramhorst, R. |
| author_sort |
Gallino, L. |
| title |
VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model |
| title_short |
VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model |
| title_full |
VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model |
| title_fullStr |
VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model |
| title_full_unstemmed |
VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model |
| title_sort |
vip treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the cbaxdba resorption prone model |
| url |
http://hdl.handle.net/20.500.12110/paper_20452322_v6_n_p_Gallino |
| work_keys_str_mv |
AT gallinol viptreatmentpreventsembryoresorptionbymodulatingefferocytosisandactivationprofileofmaternalmacrophagesinthecbaxdbaresorptionpronemodel AT calog viptreatmentpreventsembryoresorptionbymodulatingefferocytosisandactivationprofileofmaternalmacrophagesinthecbaxdbaresorptionpronemodel AT haukv viptreatmentpreventsembryoresorptionbymodulatingefferocytosisandactivationprofileofmaternalmacrophagesinthecbaxdbaresorptionpronemodel AT fraccarolil viptreatmentpreventsembryoresorptionbymodulatingefferocytosisandactivationprofileofmaternalmacrophagesinthecbaxdbaresorptionpronemodel AT grassoe viptreatmentpreventsembryoresorptionbymodulatingefferocytosisandactivationprofileofmaternalmacrophagesinthecbaxdbaresorptionpronemodel AT vermeulenm viptreatmentpreventsembryoresorptionbymodulatingefferocytosisandactivationprofileofmaternalmacrophagesinthecbaxdbaresorptionpronemodel AT leiroscp viptreatmentpreventsembryoresorptionbymodulatingefferocytosisandactivationprofileofmaternalmacrophagesinthecbaxdbaresorptionpronemodel AT ramhorstr viptreatmentpreventsembryoresorptionbymodulatingefferocytosisandactivationprofileofmaternalmacrophagesinthecbaxdbaresorptionpronemodel |
| _version_ |
1782024368051716096 |